Il Dong Pharmaceutical launches R&D subsidiary

[Courtesy of Il Dong Pharmaceutical]

South Korea’s Il Dong Pharmaceutical Co. officially launched its research and development (R&D) subsidiary, Yunovia, on Wednesday.

Former Chief Operating Officer Seo Jin-sik and former President and head of R&D Choi Sung-gu will each serve as representatives for the new R&D company, according to the company’s announcement on Thursday.

Yunovia will be engaged in the clinical development of promising pipeline products and early licensing-out of candidate substances while pursuing open innovation. It plans to secure growth momentum via fundraising and partnerships.

There are currently six to seven key new drug pipelines in areas including metabolic diseases, degenerative diseases, liver diseases, gastrointestinal diseases, and ophthalmic diseases, with a total of 25 pipelines, including ongoing new drug research projects in fields such as cancer, cardiovascular diseases, and neurological-psychiatric diseases. The company’s primary focus is on developing metabolic disease new drug candidates like “ID110521156,” targeting type 2 diabetes and obesity, and “ID119040338” for Parkinson’s disease treatment.

Yunovia said it would establish itself as a specialized leader in R&D, fostering a sustainable cycle.